NCT05451849 2025-08-27A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerTCR2 TherapeuticsPhase 1/2 Active not recruiting6 enrolled
NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts
NCT05714553 2025-07-18NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursNuCana plcPhase 1/2 Terminated19 enrolled
NCT03241173 2022-09-27A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed52 enrolled 25 charts